Towards a vaccine against the European Lyssaviruses - a structural and immunological approach

Abbreviations aa aminoacid ADCC antibody dependent cell cytotoxicity APC antigen presenting cell CFA complete Freund's adjuvant cpm counts per minute CTL cytotoxic T lymphocytes CVS challenge virus strain EBL European bat lyssavirus ERA Evelyn-Rokitmicki-Abelseth ERIG equine rabies immunoglobulin FITC fetal calf serum FITC fluoresceine isothiocyanate FFU fluorescent focus units G glycoprotein G-Bac recombinant glycoprotein expressed in G-recombinant baculovirus infected cells G-Vacc G-recombinant vaccinia virus Gs-Bac recombinant glycoprotein secreted by G-recombinant baculovirus infected cells HRIG human rabies immunoglobulin IFN interferon IL interleukin IPRV inactivated purified rabies virus IU international units L Rabies polymerase M matrix protein MHC major histocompatibility complex Mok Mokola mono monoclonal N nucleoprotein N-Bac recombinant glycoprotein expressed in N-recombinant baculovirus infected cells N-Vacc N-recombinant vaccinia virus NK natural killers NT Na-Tris-buffer OGP octylglycopyranoside P phosphoprotein PBS phosphate buffer saline PFU plaque forming unit PM Pitman Moore poly polyclonal PV Pasteur virus RNP ribonucleoprotein rpm rotations per minute TBE tris borate EDTA buffer Th T helper U unit VNA virus neutralizing antibodies VSV vesicular stomatitis virus The following parts of the results shown have been published in advance: "Production of Lyssavirus proteins in the baculovirus expression system and their use as potential vaccine" "Importance of the rabies virus glycoprotein antigenic site III and transmembrane domain for presenting foreign epitopes: use of DNA-based immunization"